Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Catalio Capital Management

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 39
Average round size
info
The average size of a deal this fund participated in
$63M
Portfolio companies 29
Rounds per year 6.50
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.23
Exits 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Life Science
  • Therapeutics
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Catalio Capital Management:
Typical Co-investors
Catalio Capital Management is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Catalio Capital Management:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Cabinet Office - GOV.UK -
Clearmind Capital China, Hong Kong, Hong Kong Island
ENERGIIQ Den Haag, The Netherlands, Zuid-Holland
Golden Summit Capital -
Guerrilla Ventures Delhi, Delhi, India
Junchuang Fund China, Guangdong, Shenzhen
Lanhua Tengge Touzi -
Mantucket Capital Management Corporation Colorado, Greenwood Village, United States
POC Clinical Research Japan, Tokyo
Visteon Belleville, Michigan, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Haystack Oncology

Biotechnology
Medical
$56M16 Nov 2022 Baltimore, Maryland, United States

Fractyl Laboratories

Biotechnology
Health Care
Medical Device
Wellness
15 Aug 2022 Massachusetts, United States

Cartography Biosciences

Biotechnology
Life Science
$57M19 Jul 2022 Foster City, California, United States

Xilis

Biotechnology
Health Care
Health Diagnostics
Life Science
Pharmaceutical
$19M13 Jul 2022 Durham, North Carolina, United States

Anagenex

Biotechnology
Information Technology
Life Science
$30M08 Jun 2022 -

Clover Therapeutics

Biotechnology
Health Care
$18M17 May 2022 Jersey City, New Jersey, United States

Octant Bio

Biotechnology
Life Science
$80M28 Apr 2022 Los Angeles, California, United States

Pheast Therapeutics

Biotechnology
$76M26 Apr 2022 Palo Alto, California, United States

Octant Bio

Biotechnology
Life Science
$80M21 Apr 2022 Los Angeles, California, United States
News
DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform

– DNA Script announced it has raised $165m in a Series C financing round.
– The round was led by Coatue Management and Catalio Capital Management, whose representatives have joined as Board observers.
– The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.
– The SYNTAX Platform provides in-house DNA printing – without using toxic organic chemicals or extended delivery wait times from third-party DNA service providers – for labs of all sizes.

Entos Raises $53 Million Series A Round Led by Coatue and Catalio

– Entos, Inc. (“Entos” or “the Company”), the creator of a cutting-edge platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, announced the closing of a $53 million Series A.
– The financing round was led by Coatue, a leading technology investment firm, and Catalio Capital Management, a leading biomedical technology investment firm, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Catalio Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: